Supercarrier Prodrug
Metastatic Melanoma
Pre-clinicalActive
Key Facts
About Temprian Oncology
Temprian Oncology is a private, preclinical biotech founded in 2021 and based in San Diego, with research roots at Northwestern University. The company is advancing a novel nanoparticle prodrug platform, termed 'Supercarriers,' which targets metastatic melanoma by releasing an active drug specifically within the acidic pigment organelles of tumor cells. This approach seeks to improve efficacy and reduce side effects, positioning it as a potential successor or complement to current tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). The company is pre-revenue, with a patent pending on its core technology.
View full company profileTherapeutic Areas
Other Metastatic Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| ADZE1.C | Adze Biotechnology | Phase 1 |
| EVX-01 | Evaxion | Phase 2 |
| Opdualag (nivo + relatlimab) | Ono Pharmaceutical | Approved |
| APG-115 (Alrizomadlin) | Ascentage Pharma Group | Phase 2 |